Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Baxter International Inc (BAX) vs Moderna, Inc. (MRNA) Price & Performance

Baxter International IncTrade
Moderna, Inc.Trade

Price performance (Past 24H)

Key statistics

Baxter International Inc vs Moderna, Inc. — how do they compare? Baxter International Inc trades at $27.08 (market cap $14.27B), while Moderna, Inc. trades at $63.65 (market cap $24.18B). The key difference: Moderna, Inc. is the larger of the two by market cap, and Baxter International Inc pays a 0.14% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.

BAXMRNA
Market Cap
$14.27B$24.18B
Sector
HealthHealth
52-Week High
$28.35$81.80
52-Week Low
$15.80$22.36
Enterprise Value
$21.79B$20.33B
Dividend Yield
0.14%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Baxter International Inc

Baxter International (BAX) trades at $27.09, down 2.48% today but showing strong technical momentum with bullish moving averages and recent earnings beats. The company reported Q2 2026 EPS of $0.56, beating expectations by 53%, and raised full-year guidance. Despite negative net margins and elevated P/E ratio of 87.85, improving operational performance and positive cash flow projections for 2026 suggest potential turnaround.

The stock presents a mixed outlook with strong technical momentum and recent operational improvements offset by valuation concerns and profitability challenges. Key opportunities include continued execution on raised guidance and debt reduction efforts, while risks center on margin pressure and high debt levels. Analyst consensus leans neutral with 55.55% hold ratings and $25.43 price target below current levels.

Moderna, Inc.

Moderna (MRNA) trades at $63.57, up 6.29% on the day, reflecting positive momentum following FDA approval of its mRNA flu vaccine, mFLUSIVA, for adults 50 and older. The stock exhibits a bullish technical outlook with moving averages supporting upward movement, though RSI levels suggest potential overbought conditions. Fundamentally, revenue has declined from pandemic peaks, with 2025 revenue at $1.92B and a net loss of -$2.82B, yet the company has beaten EPS estimates in recent quarters. Cash flow trends show improvement, with net cash flow turning positive in 2025 at $668M.

The outlook for MRNA hinges on pipeline execution beyond COVID-19, with recent vaccine approvals providing growth catalysts. Investment opportunities include diversification into flu, Ebola, and oncology therapies, but risks persist from high cash burn, competitive pressures, and reliance on successful clinical trials. Analyst sentiment is mixed with a consensus price target of $54.33, below the current price, indicating caution despite some bullish developments.

Returns comparison

Trailing returns across standard periods

About Baxter International Inc

Baxter offers a variety of medical instruments and supplies to caregivers. It enhanced its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021. Legacy Baxter offers tools to help patients with acute and chronic kidney failure. It also sells a variety of injectable therapies for use in care settings, such as IV pumps, and administrative sets.

Read more on BAX

About Moderna, Inc.

Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.

Read more on MRNA